BG64168B1 - Бързоразтворима таблета на галантамин хидробромид - Google Patents
Бързоразтворима таблета на галантамин хидробромид Download PDFInfo
- Publication number
- BG64168B1 BG64168B1 BG102991A BG10299198A BG64168B1 BG 64168 B1 BG64168 B1 BG 64168B1 BG 102991 A BG102991 A BG 102991A BG 10299198 A BG10299198 A BG 10299198A BG 64168 B1 BG64168 B1 BG 64168B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- tablet
- sample
- tablet according
- film coating
- disintegrant
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title claims description 54
- 229960003980 galantamine Drugs 0.000 title claims description 35
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title description 19
- 239000000203 mixture Substances 0.000 claims abstract description 25
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims abstract description 13
- 229960001021 lactose monohydrate Drugs 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 239000007888 film coating Substances 0.000 claims description 23
- 238000009501 film coating Methods 0.000 claims description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 239000007884 disintegrant Substances 0.000 claims description 11
- 239000011363 dried mixture Substances 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 2
- 229960005168 croscarmellose Drugs 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
- 238000000151 deposition Methods 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 12
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 abstract description 12
- 229960002024 galantamine hydrobromide Drugs 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 4
- 239000001913 cellulose Substances 0.000 abstract description 3
- 238000003825 pressing Methods 0.000 abstract description 2
- 238000000889 atomisation Methods 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 51
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 12
- 239000000454 talc Substances 0.000 description 10
- 229910052623 talc Inorganic materials 0.000 description 10
- 239000004408 titanium dioxide Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 7
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 7
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 7
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 7
- 239000008213 purified water Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 238000007907 direct compression Methods 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229920003125 hypromellose 2910 Polymers 0.000 description 4
- 229940031672 hypromellose 2910 Drugs 0.000 description 4
- 229960003511 macrogol Drugs 0.000 description 4
- 239000007944 soluble tablet Substances 0.000 description 4
- DITOENWBJBNZSL-UHFFFAOYSA-N O-methyl-hippeastrine Natural products C1=C2C3C4N(C)CCC4=CC(OC)C3OC(=O)C2=CC2=C1OCO2 DITOENWBJBNZSL-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 229940100445 wheat starch Drugs 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000003797 alkaloid derivatives Chemical group 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000013383 initial experiment Methods 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- DKXNBNKWCZZMJT-JVCRWLNRSA-N (2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound O=C[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DKXNBNKWCZZMJT-JVCRWLNRSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- JPVBTFOTYRZBLR-UHFFFAOYSA-N 2h-2-benzazepin-6-ol Chemical compound N1C=CC=C2C(O)=CC=CC2=C1 JPVBTFOTYRZBLR-UHFFFAOYSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000001375 Facial Neuralgia Diseases 0.000 description 1
- 241000234271 Galanthus Species 0.000 description 1
- 241001502107 Galanthus alpinus Species 0.000 description 1
- 241000234283 Galanthus nivalis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101100532451 Rattus norvegicus Slc22a17 gene Proteins 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- -1 macrogol 6000 Chemical compound 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96201676 | 1996-06-14 | ||
| PCT/EP1997/002986 WO1997047304A1 (en) | 1996-06-14 | 1997-06-06 | Fast-dissolving galanthamine hydrobromide tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG102991A BG102991A (en) | 1999-08-31 |
| BG64168B1 true BG64168B1 (bg) | 2004-03-31 |
Family
ID=8224084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG102991A BG64168B1 (bg) | 1996-06-14 | 1998-12-04 | Бързоразтворима таблета на галантамин хидробромид |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US6099863A (cs) |
| EP (1) | EP0915701B1 (cs) |
| JP (1) | JP4172820B2 (cs) |
| KR (1) | KR100358676B1 (cs) |
| CN (1) | CN1102390C (cs) |
| AR (2) | AR008237A1 (cs) |
| AT (1) | ATE285777T1 (cs) |
| AU (1) | AU726212B2 (cs) |
| BG (1) | BG64168B1 (cs) |
| BR (1) | BR9709729A (cs) |
| CA (1) | CA2257431C (cs) |
| CZ (1) | CZ295226B6 (cs) |
| DE (1) | DE69732113T2 (cs) |
| DK (1) | DK0915701T3 (cs) |
| EA (1) | EA001193B1 (cs) |
| EE (1) | EE03337B1 (cs) |
| ES (1) | ES2235234T3 (cs) |
| HR (1) | HRP970321B1 (cs) |
| ID (1) | ID17088A (cs) |
| IL (1) | IL127519A (cs) |
| MY (1) | MY121669A (cs) |
| NO (1) | NO322892B1 (cs) |
| NZ (1) | NZ333280A (cs) |
| PL (1) | PL189329B1 (cs) |
| PT (1) | PT915701E (cs) |
| SI (1) | SI0915701T1 (cs) |
| SK (1) | SK284620B6 (cs) |
| TR (1) | TR199802592T2 (cs) |
| TW (1) | TW506836B (cs) |
| UA (1) | UA62930C2 (cs) |
| WO (1) | WO1997047304A1 (cs) |
| ZA (1) | ZA975281B (cs) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440457B1 (en) * | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
| CA2358062C (en) | 1998-12-24 | 2006-12-19 | Janssen Pharmaceutica N.V. | Controlled release galantamine composition |
| US20050063998A1 (en) * | 1999-10-26 | 2005-03-24 | Francois Marc Karel Jozef | Oral solution containing galantamine and a sweetening agent |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| WO2001078721A1 (en) * | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | Aβ42 LOWERING AGENTS |
| SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| US6500454B1 (en) * | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| EA013069B1 (ru) * | 2002-04-02 | 2010-02-26 | Янссен Фармацевтика Н.В. | Статиновая терапия для усиления поддержания когнитивной функции |
| DE10235556A1 (de) * | 2002-08-03 | 2004-02-19 | Hf Arzneimittelforschung Gmbh | Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums |
| US20040097484A1 (en) * | 2002-11-14 | 2004-05-20 | Marc Cantillion | Once a day galantamine pharmaceutical compositions and methods of use |
| EP3473251B1 (en) | 2002-12-20 | 2023-12-13 | NicoNovum AB | A nicotine-cellulose combination |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| EA012798B1 (ru) * | 2003-08-26 | 2009-12-30 | Шир Холдингз Аг | Фармацевтический состав, содержащий карбонат лантана (варианты) |
| US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| WO2005051489A2 (en) * | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | Fast dissolving solid oral dosage forms of galanthamine |
| US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
| EP2340813A1 (en) * | 2003-12-31 | 2011-07-06 | Actavis Group PTC ehf. | Solid dosage formulations of galantamine |
| WO2005065662A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| BRPI0514303A (pt) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | composição farmacêutica e método para tratar distúrbios neurodegenerativos |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| PL2813225T3 (pl) * | 2004-09-24 | 2018-11-30 | University Of Maryland, Baltimore | Sposób leczenia zatrucia związkami fosforoorganicznymi |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| NZ709754A (en) | 2004-10-21 | 2017-02-24 | Adare Pharmaceuticals Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| EP1819681B1 (en) * | 2004-11-23 | 2009-08-12 | Warner-Lambert Company LLC | 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
| US20080145422A1 (en) * | 2005-02-10 | 2008-06-19 | Roxane Laboratories, Inc. | Galantamine tablet formulation |
| US9161918B2 (en) * | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| GB0516604D0 (en) * | 2005-08-12 | 2005-09-21 | Sandoz Ag | Rapidly dispersing/disintegrating compositions |
| US8168219B2 (en) * | 2005-11-30 | 2012-05-01 | Isp Investments Inc. | Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability |
| WO2007104573A2 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
| ES2572180T3 (es) * | 2006-04-26 | 2016-05-30 | Alphapharm Pty Ltd | Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| WO2008008120A1 (en) * | 2006-07-14 | 2008-01-17 | Fmc Corporation | Solid form |
| CN100438917C (zh) * | 2006-07-20 | 2008-12-03 | 山东聊城阿华制药有限公司 | 一种微晶纤维素乳糖的制备方法 |
| WO2008062426A2 (en) * | 2006-08-02 | 2008-05-29 | Emcure Pharmaceuticals Limited | Formulation of benzazepine derivatives |
| CA2667553A1 (en) | 2006-10-27 | 2008-05-02 | Medivation Neurology, Inc. | Methods and combination therapies for treating alzheimer's disease |
| US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
| PE20091156A1 (es) * | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
| ATE545410T1 (de) | 2008-05-09 | 2012-03-15 | Ratiopharm Gmbh | Galanthaminhaltiges arzneimittel mit kontrollierter freisetzung |
| AU2010325746B2 (en) | 2009-12-02 | 2016-02-25 | Adare Pharmaceuticals S.R.L. | Fexofenadine microcapsules and compositions containing them |
| WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
| JP5656258B2 (ja) * | 2011-03-09 | 2015-01-21 | 塩野義製薬株式会社 | ガランタミンを含有する口腔内崩壊錠剤 |
| US10357486B2 (en) | 2013-08-16 | 2019-07-23 | Universiteit Maastricht | Treatment of cognitive impairment with PDE4 inhibitor |
| CN106822008A (zh) * | 2017-01-11 | 2017-06-13 | 江苏艾兰得营养品有限公司 | 一种维生素d速溶制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3506276C1 (de) * | 1985-02-22 | 1986-04-24 | Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring | Direkttablettiermittel |
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| US5312817A (en) * | 1991-05-14 | 1994-05-17 | Ernir Snorrason | Treatment of fatigue syndrome |
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
-
1997
- 1997-05-19 TW TW086106622A patent/TW506836B/zh not_active IP Right Cessation
- 1997-06-06 KR KR10-1998-0709401A patent/KR100358676B1/ko not_active Expired - Lifetime
- 1997-06-06 PL PL97330431A patent/PL189329B1/pl unknown
- 1997-06-06 US US09/202,187 patent/US6099863A/en not_active Expired - Lifetime
- 1997-06-06 EE EE9800429A patent/EE03337B1/xx unknown
- 1997-06-06 BR BR9709729A patent/BR9709729A/pt not_active IP Right Cessation
- 1997-06-06 PT PT97927159T patent/PT915701E/pt unknown
- 1997-06-06 AT AT97927159T patent/ATE285777T1/de active
- 1997-06-06 WO PCT/EP1997/002986 patent/WO1997047304A1/en not_active Ceased
- 1997-06-06 DK DK97927159T patent/DK0915701T3/da active
- 1997-06-06 CA CA002257431A patent/CA2257431C/en not_active Expired - Lifetime
- 1997-06-06 EA EA199900026A patent/EA001193B1/ru not_active IP Right Cessation
- 1997-06-06 IL IL12751997A patent/IL127519A/en not_active IP Right Cessation
- 1997-06-06 CZ CZ19984034A patent/CZ295226B6/cs not_active IP Right Cessation
- 1997-06-06 SK SK1696-98A patent/SK284620B6/sk not_active IP Right Cessation
- 1997-06-06 UA UA98126372A patent/UA62930C2/uk unknown
- 1997-06-06 AU AU31743/97A patent/AU726212B2/en not_active Expired
- 1997-06-06 CN CN97195512A patent/CN1102390C/zh not_active Expired - Lifetime
- 1997-06-06 DE DE69732113T patent/DE69732113T2/de not_active Expired - Lifetime
- 1997-06-06 SI SI9730690T patent/SI0915701T1/xx unknown
- 1997-06-06 NZ NZ333280A patent/NZ333280A/en not_active IP Right Cessation
- 1997-06-06 JP JP50118198A patent/JP4172820B2/ja not_active Expired - Lifetime
- 1997-06-06 ES ES97927159T patent/ES2235234T3/es not_active Expired - Lifetime
- 1997-06-06 TR TR1998/02592T patent/TR199802592T2/xx unknown
- 1997-06-06 EP EP97927159A patent/EP0915701B1/en not_active Expired - Lifetime
- 1997-06-11 HR HR970321A patent/HRP970321B1/xx not_active IP Right Cessation
- 1997-06-12 MY MYPI97002621A patent/MY121669A/en unknown
- 1997-06-13 ID IDP972025A patent/ID17088A/id unknown
- 1997-06-13 ZA ZA975281A patent/ZA975281B/xx unknown
- 1997-06-13 AR ARP970102615A patent/AR008237A1/es active IP Right Grant
-
1998
- 1998-12-04 BG BG102991A patent/BG64168B1/bg unknown
- 1998-12-11 NO NO19985815A patent/NO322892B1/no not_active IP Right Cessation
-
2000
- 2000-06-01 US US09/585,122 patent/US6358527B1/en not_active Expired - Lifetime
-
2008
- 2008-11-25 AR ARP080105111A patent/AR070670A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG64168B1 (bg) | Бързоразтворима таблета на галантамин хидробромид | |
| FI89005B (fi) | Foerfarande foer framstaellning av en doseringsform av etodolac med foerdroejd utloesning | |
| RU2403043C2 (ru) | Подъязычная таблетка, покрытая оболочкой | |
| US4309406A (en) | Sustained release pharmaceutical compositions | |
| ZA200403849B (en) | Pharmaceutical composition | |
| NZ220769A (en) | Compositions of ketotifen (4-(1-methyl-4-piperidylidene)- 4h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-9(h)-one) | |
| JP2011507973A (ja) | アムロジピンとバルサルタンとの医薬組成物 | |
| US20090264408A1 (en) | Extended release dosage forms of quetiapine | |
| AU2005263958B2 (en) | Anti-histaminic composition | |
| CA2247405C (en) | Slow-release pharmaceutical formulations containing mizolastin | |
| RU2256454C2 (ru) | Способы получения фармацевтических композиций алкалоидов спорыньи с пролонгированным действием, характеризующихся улучшенной биодоступностью, и содержащие указанные алкалоиды композиции | |
| JP2001511450A (ja) | チアガビンを含有する制御放出性の医薬組成物 | |
| KR102545579B1 (ko) | iLet (innovation low excipient tablet) 기술을 이용한 정제사이즈 축소를 통해 복용편의성이 증가된 카르베딜롤 서방성 정제 | |
| CA2180703A1 (en) | Fast-dissolving galanthamine hydrobromide tablet | |
| US20030180354A1 (en) | Amlodipine maleate formulations | |
| HU226132B1 (en) | Fast-dissolving galanthamine hydrobromide tablet | |
| HK1019703B (en) | Fast-dissolving galanthamine hydrobromide tablet | |
| AU2012202717B2 (en) | Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion | |
| HK1068539A1 (en) | Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient | |
| HK1068539B (en) | Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient | |
| HK1077003A1 (en) | Sustained release formulations comprising lamotrigine |